Guggenheim assumed coverage on shares of Health Catalyst (NASDAQ:HCAT – Get Rating) in a research report issued to clients and investors on Wednesday, The Fly reports. The firm set a “buy” rating on the stock.
A number of other equities research analysts have also recently issued reports on HCAT. Jefferies Financial Group raised shares of Health Catalyst from a “hold” rating to a “buy” rating and lowered their target price for the company from $31.00 to $28.00 in a report on Thursday, March 17th. Canaccord Genuity Group lowered their target price on shares of Health Catalyst from $62.00 to $35.00 in a report on Wednesday, March 2nd. BTIG Research reduced their price target on shares of Health Catalyst from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Friday, March 25th. Royal Bank of Canada reduced their price target on shares of Health Catalyst from $66.00 to $35.00 and set an “outperform” rating for the company in a research report on Wednesday, March 2nd. Finally, The Goldman Sachs Group assumed coverage on shares of Health Catalyst in a research report on Friday, February 11th. They set a “buy” rating and a $48.00 price target for the company. One analyst has rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $44.69.
HCAT stock traded down $0.24 during midday trading on Wednesday, reaching $24.03. 350,991 shares of the company’s stock traded hands, compared to its average volume of 583,499. The company has a 50-day moving average price of $26.15 and a two-hundred day moving average price of $36.63. The company has a debt-to-equity ratio of 0.35, a quick ratio of 5.46 and a current ratio of 5.46. Health Catalyst has a 52 week low of $20.39 and a 52 week high of $59.50. The firm has a market capitalization of $1.25 billion, a PE ratio of -7.49 and a beta of 0.89.
Health Catalyst (NASDAQ:HCAT – Get Rating) last issued its earnings results on Tuesday, March 1st. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.02. Health Catalyst had a negative net margin of 63.33% and a negative return on equity of 21.30%. The business had revenue of $64.72 million for the quarter, compared to analysts’ expectations of $63.17 million. During the same quarter in the previous year, the firm posted ($0.41) EPS. The business’s revenue for the quarter was up 21.5% compared to the same quarter last year. As a group, analysts predict that Health Catalyst will post -1.8 EPS for the current fiscal year.
In related news, COO Paul Horstmeier sold 10,750 shares of the firm’s stock in a transaction that occurred on Monday, February 7th. The shares were sold at an average price of $29.10, for a total value of $312,825.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Linda Llewelyn sold 2,039 shares of the firm’s stock in a transaction that occurred on Tuesday, March 15th. The stock was sold at an average price of $21.08, for a total transaction of $42,982.12. The disclosure for this sale can be found here. In the last quarter, insiders have sold 41,889 shares of company stock worth $1,103,730. Corporate insiders own 2.00% of the company’s stock.
A number of hedge funds have recently modified their holdings of HCAT. UMB Bank N A MO bought a new position in Health Catalyst in the fourth quarter worth approximately $30,000. Sageworth Trust Co of South Dakota bought a new stake in shares of Health Catalyst during the 4th quarter valued at $61,000. Advisor Group Holdings Inc. raised its position in shares of Health Catalyst by 27.3% during the 3rd quarter. Advisor Group Holdings Inc. now owns 1,466 shares of the company’s stock valued at $73,000 after purchasing an additional 314 shares during the period. O Shaughnessy Asset Management LLC grew its stake in Health Catalyst by 23.3% during the third quarter. O Shaughnessy Asset Management LLC now owns 2,452 shares of the company’s stock valued at $123,000 after acquiring an additional 463 shares in the last quarter. Finally, Strs Ohio grew its stake in Health Catalyst by 50.0% during the third quarter. Strs Ohio now owns 3,300 shares of the company’s stock valued at $165,000 after acquiring an additional 1,100 shares in the last quarter.
Health Catalyst Company Profile (Get Rating)
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its solutions include a cloud-based data platform, analytics software, and professional services. The company was formerly known as HQC Holdings, Inc and changed its name to Health Catalyst, Inc in March 2017.
Receive News & Ratings for Health Catalyst Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Health Catalyst and related companies with MarketBeat.com’s FREE daily email newsletter.